These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 4042084)

  • 1. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.
    Carter WH
    Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084
    [No Abstract]   [Full Text] [Related]  

  • 2. Factorial designs for randomized clinical trials.
    Byar DP; Piantadosi S
    Cancer Treat Rep; 1985 Oct; 69(10):1055-63. PubMed ID: 4042085
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.
    Mietlowski W; Wang J
    Contemp Clin Trials; 2007 Sep; 28(5):674. PubMed ID: 17449334
    [No Abstract]   [Full Text] [Related]  

  • 5. An efficient design for phase III studies of combination chemotherapies.
    Ellenberg SS; Eisenberger MA
    Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy for adult soft tissue sarcoma. Does it work?
    Saeter G
    Acta Orthop Scand Suppl; 1997 Feb; 273():139-44. PubMed ID: 9057605
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of measurement error on response rates.
    Warr D; McKinney S; Tannock I
    Cancer Treat Rep; 1985 Oct; 69(10):1127-32. PubMed ID: 4042092
    [No Abstract]   [Full Text] [Related]  

  • 8. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
    Emerson SS
    Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 11. Is response rate relevant to the phase II trial design of targeted agents?
    Dowlati A; Fu P
    J Clin Oncol; 2008 Mar; 26(8):1204-5. PubMed ID: 18285601
    [No Abstract]   [Full Text] [Related]  

  • 12. [Why is it sometimes necessary to include a large number of patients in clinical trials?].
    Hill C
    Bull Cancer; 1989; 76(6):569-71. PubMed ID: 2570613
    [No Abstract]   [Full Text] [Related]  

  • 13. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
    Markman M
    Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current status and issues in clinical trials of anticancer agents].
    Kojima H
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy in head and neck cancer: what should we expect?
    Büntzel J; Micke O
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):269-73. PubMed ID: 19275504
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?
    Bhutani M; Pathak AK
    J Natl Cancer Inst; 2008 Sep; 100(18):1334; author reply 1334-5. PubMed ID: 18780866
    [No Abstract]   [Full Text] [Related]  

  • 17. Discrete event simulation applied to pediatric phase I oncology designs.
    Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
    Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Nagourney RA
    Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464
    [No Abstract]   [Full Text] [Related]  

  • 19. Modelling chemotherapy resistance in palliation and failed cure.
    Monro HC; Gaffney EA
    J Theor Biol; 2009 Mar; 257(2):292-302. PubMed ID: 19135065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.